Lead Product(s): Rhenium-186
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Plus Therapeutics
Deal Size: $137.2 million Upfront Cash: $0.4 million
Deal Type: Licensing Agreement May 11, 2020
Plus Therapeutics closed its previously announced definitive agreement to license multiple rare cancer product candidates that includes, Rhenium-186-chelated NanoLiposome from NanoTx Therapeutics.